TG1050, an immunotherapeutic to treat chronic hepatitis B, induces robust T cells and exerts an antiviral effect in HBV-persistent mice

OBJECTIVE: To assess a new adenovirus-based immunotherapy as a novel treatment approach to chronic hepatitis B (CHB). METHODS: TG1050 is a non-replicative adenovirus serotype 5 encoding a unique large fusion protein composed of a truncated HBV Core, a modified HBV Polymerase and two HBV Envelope dom...

Descripción completa

Detalles Bibliográficos
Autores principales: Martin, Perrine, Dubois, Clarisse, Jacquier, Emilie, Dion, Sarah, Mancini-Bourgine, Maryline, Godon, Ophélie, Kratzer, Roland, Lelu-Santolaria, Karine, Evlachev, Alexei, Meritet, Jean-François, Schlesinger, Yasmin, Villeval, Dominique, Strub, Jean-Marc, Van Dorsselaer, Alain, Marchand, Jean-Baptiste, Geist, Michel, Brandely, Renée, Findeli, Annie, Boukhebza, Houda, Menguy, Thierry, Silvestre, Nathalie, Michel, Marie-Louise, Inchauspé, Geneviève
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2015
Materias:
Hepatology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4680198/
https://www.ncbi.nlm.nih.gov/pubmed/25429051
http://dx.doi.org/10.1136/gutjnl-2014-308041

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4680198/
https://www.ncbi.nlm.nih.gov/pubmed/25429051
http://dx.doi.org/10.1136/gutjnl-2014-308041

Ejemplares similares